【摘要】 目的 探索非小细胞肺癌(NSCLC)高效、低毒副反应的化疗模式。方法 72例非小细胞肺癌(TNM分期为Ⅲ、Ⅳ期)入组，紫杉醇60～80mg/m2,静点，第1天：顺铂40～60mg/m2，第1天；每周化疗1次，连续4～6周，无需水化。结果 本组共治疗184个疗程，CR 9例，PR 30例，SD 24例，PD 9例，有效缓解率54.2%，中位缓解率6.0个月，1年生存率56.9%。本组有效缓解率和1年生存率均高于同期随机入组的高冲式化疗组，但差异无显著性(P>0.05),重度(Ⅲ+Ⅳ度)毒副反应率低于对照组。同时化疗后生活质量上升的比例(70.8%)高于对照组(51.9%)，差异有显著性(P<0.05)。结论 低剂量密集式化疗采用低剂量、短间歇式、频投药的方法，提高了剂量强度，化疗效果好，毒副反应轻，对生活质量的影响小。

    【关键词】 非小细胞肺癌；低剂量；密集式

    The clinical application of paclitaxel combined with DDP(cisplatin) regimen in the low dose and short interval duration treatment for non-small-cell lung cancer

    LIU Yu-guang,LIU Feng-lin,XU Li,et al.

    Department of Thorax,Jilin Provincial Hospital of Oncology,Changchun 130012,China

    【Abstract】 Objective To explore high effective and low toxic chemotherapeutic regimen in the treatment of non-small-cell lung cancer (NSCLC).Methods Seventy-two patients in LDDC group were given paclitaxel 60～80mg/m2 on day 1, DDP 40～80mg/m2 on day 1 repeated weekly,in a 4～6 weeks cycle.Results Of 184 courses in LDDC group,an average of 2.6 courses per patient,CR 9,PR 30,SD24 and PD 9 were observed. The effective remission rate was 54.2%,the median effective remission period was 6 months and the 1-year survival rate was 56.9%.The effective remission rate and the 1-year survival rate were higher in HDIC group than those in LDDC group, but there was no statistical difference between the two groups(P>0.05). Severe toxicity was higher in HDIC group than in LDDC group.Quality of life was better in LDDC group(70.8%)than in HDIC group(51.9%).Conclusion When comparing with high dose impulsion, low dose density regimen of paclitaxel plus cisplatin is more effective and better tolerated with improvement of quality of patients' life in the treatment of NSCLC due to its low dose and short interval duration. ......